Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35541
Title: Amino Acid Infusion for Perioperative Functional Renal Protection: A Meta-analysis.
Austin Authors: Pruna, Alessandro;Losiggio, Rosario;Landoni, Giovanni;Kotani, Yuki;Redaelli, Martina Baiardo;Veneziano, Marta;Lee, Todd C;Zangrillo, Alberto;Gaudino, Mario F L;Bellomo, Rinaldo 
Affiliation: Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Intensive Care
Data Analytics Research and Evaluation (DARE) Centre
Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia.
Issue Date: Dec-2024
Date: 2024
Publication information: Journal of Cardiothoracic and Vascular Anesthesia 2024-12; 38(12)
Abstract: Acute kidney injury (AKI) is a common perioperative complication. To date, no single intervention has been proven effective for AKI prevention in this setting. However, intravenous amino acids (AA) administration may recruit renal functional reserve and, thereby, attenuate the perioperative loss of the glomerular filtration rate. We performed a meta-analysis to assess the efficacy of AA infusion for perioperative renal functional protection. We performed a meta-analysis of controlled studies in perioperative patients evaluating intravenous AA infusion versus any comparator. The primary outcome was AKI at longest follow-up. We performed a random effects meta-analysis on the relative risk (RR) scale to assess the effect of AA infusion. We used a Bayesian approach to estimate the probability of benefit (RR < 1) for the primary outcome. Secondary outcomes included renal replacement therapy, serum creatinine, and estimated glomerular filtration rate. Tertiary outcomes included mechanical ventilation duration, intensive care unit and hospital length of stay and mortality (PROSPERO: CRD42024547225). We identified 15 studies (14 randomized controlled trials and 1 prospective before-after study) reporting at least one outcome of interest (4,544 patients), with 6 studies (4,084 patients) reporting the primary outcome. AKI occurred 504 of 2,041 (24.7%) in AA patients versus 614 of 2,041 (30.1%) in controls (RR, 0.66; 95% confidence interval, 0.47-0.94; I2 = 50%; p = 0.02), which corresponded with a 99.1% probability of AKI reduction with AA. Moreover, consistent with these findings, AA decreased serum creatinine and hospital length of stay and increased the estimated glomerular filtration rate. This meta-analysis suggests that AA administration likely decreased the perioperative incidence of AKI.
URI: https://ahro.austin.org.au/austinjspui/handle/1/35541
DOI: 10.1053/j.jvca.2024.08.033
ORCID: 
Journal: Journal of Cardiothoracic and Vascular Anesthesia
PubMed URL: 39384419
ISSN: 1532-8422
Type: Journal Article
Subjects: acute kidney injury
amino acids
anesthesia
perioperative
renal protection
Appears in Collections:Journal articles

Show full item record

Page view(s)

22
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.